Prospective, Longitudinal, Non-Interventional
Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401), NCT02953704
PURPOSE OF THIS CLINICAL RESEARCH TRIAL:
The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).
MORE DETAILS ON THIS GENERAL ONCOLOGY TRIAL:
16092 / NCT02953704 / Open 2-23-2017
TRIAL AVAILABLE AT THESE LOCATIONS: